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ABSTRACT
Objective: The present paper describes a simple, accurate, and precise reversed-phase high-performance liquid chromatography (HPLC) method for 
rapid and simultaneous quantification of netupitant (NTP) and palonosetron (PLS) in bulk and pharmaceutical dosage form.
Methods: The chromatographic separation was achieved on Luna C18 (250 mm × 4.6 mm, 5 µ). Mobile phase contained a mixture of 0.1% 
orthophosphoric acid and acetonitrile in the ratio of 60:40 v/v, flow rate 1.0 ml/min, and ultraviolet detection at 222 nm.
Results: The proposed method shows a good linearity in the concentration range of 60–900 µg/ml for NTP and 0.1–1.5 µg/ml for PLS under 
optimized conditions. All the precision and recovery results are in between 98 and 102%. In the entire robustness conditions, percentage of relative 
standard deviation is <2.0%. Degradation has minimum effect in stress condition and solutions are stable up to 24 h. This method is validated different 
parameters such as precision, linearity, accuracy, limit of detection, limit of quantification, ruggedness, robustness, and forced degradation study were 
determined according to the International Conference of Harmonization (ICH) Q2B guidelines.
Conclusion: All the parameters of validation were found to be within the acceptance range of ICH guidelines. Since there is no HPLC method reported 
in the literature for the estimation of NTP and PLS in pharmaceutical dosage forms, there is a need to develop quantitative methods under different 
conditions to achieve improvement in sensitivity, selectivity, etc. Hence, the author has attempted to develop a validation and forced degradation for 
simultaneous quantification of NTP and PLS.
Keywords: Reversed-phase-high-performance liquid chromatography, Netupitant, Palonosetron.
INTRODUCTION
Netupitant (NTP) is a novel antiemetic [1,2] drug in the combination 
of NTP/palonosetron (PLS). It is used to the prevention of acute and 
delayed chemotherapy-induced nausea and vomiting [3], including 
highly emetogenic [4] chemotherapy [5] such as with cisplatin [6]. 
5-hydroxytryptamine (5-HT3) receptors [7] are located on the nerve 
terminals [8] of the vagus [9] in the periphery and centrally in the 
chemoreceptor [10] trigger zone of the area postrema [11]. It is 
thought that chemotherapeutic agents produce nausea and vomiting by 
releasing serotonin [12] then activate 5-HT3 receptors located on vagal 
afferents [13] to initiate the vomiting reflex.
The review of literature revealed that several analytical methods 
have been reported for NTP and PLS in spectrophotometry, high-
performance liquid chromatography (HPLC), high-performance thin-
layer chromatography [14-22] individually, and in the combination. 
To date, there are no reports for stability-indicating simultaneous 
estimation and forced degradation study of NTP and PLS.
METHODS
Instrumentation
The analysis was performed on Water Alliance e-2695 chromatographic 
system equipped with a quaternary pump and photodiode array 
detector (PDA)-2996. Chromatographic software empower-2.0 was 
used for data collection.
Chemicals and reagents
Acetonitrile (HPLC grade), orthophosphoric acid (OPA) (HPLC grade), 
and Water (HPLC grade) were purchased from Merck (India) Ltd., 
Worli, Mumbai, India. Active pharmaceutical ingredients (APIs) of NTP 
and PLS reference standards were produced from Supriya Lifescience, 
Mumbai, India.
Chromatographic conditions
Chromatographic analysis was done using isocratic elution, mobile 
phase in the ratio of acetonitrile:buffer (0.1% OPA) (40:60 v/v) was 
filtered through 0.45 µ membrane filter paper. The flow rate of the 
mobile phase was monitored at 1.0 ml/min and eluents were detected 
at 222 nm. By injecting the volume 10 µl with a run time 10 min. 
Selection of wavelength
Using PDA detector, the absorption spectra of the solution of two drugs are 
scanned in the ultraviolet region of 200–400 nm spectra shown in Fig. 1, 
the spectra of the NTP and PLS shown at different λmax, namely 245.0 and 
273.3 nm, respectively. By overlay of the two spectra combined at 222 nm 
was selected as detection wavelength for HPLC chromatographic method.
Preparation of standard solution
600 mg of NTP working standard taken into a 100 ml volumetric flask. 
Add 70 ml of mobile phase sonicated for 20 min to dissolve makeup to 
the mark with mobile phase.
10 mg of PLS working standard taken into a 10 ml volumetric flask. Add 
7 ml of mobile phase sonicated for 20 min to dissolve makeup to the 
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mark with mobile phase. Further, dilute 1 ml of above solution to 50 ml 
with mobile phase.
Further, diluted each 5 ml of above two solutions to 50 ml with mobile 
phase.
Preparation of sample solution
Weigh 20 tablets and take the one tablet equivalent weight. Crush 
the 20 tablets into powder form, take 640 mg of sample into a 100 ml 
volumetric flask, and add 70 ml mobile phase sonicated for 30 min after 
that make up to the mark with mobile phase.
Validation
System suitability
As per the test method, the standard solutions were prepared and 
injected into HPLC system from which the evaluated system suitability 
parameters are found to be within the limits.
Linearity
The ability of the method to produce results those are directly or 
indirectly proportional to the concentration of the analyst in samples 
within the limits.
Precision
The degree of the closeness of agreement among individual test results 
when a method is applied to multiple samplings of a homogeneous 
sample. It is a measure of either the degree of reproducibility 
(agreement under different conditions) or repeatability (agreement 
under the same conditions) of the method.
Accuracy
The closeness of results was obtained by a method to the true value. It 
is a measure of the exactness of the method.
Limit of detection (LOD) and limit of quantification (LOQ)
The LOD and LOQ for each analyte were determined based on a signal-
to-noise concept, as the lowest concentration at which signal-to-noise 
ratio between 3 or 2:1 and 10:1, respectively, with defined precision 
and accuracy under the given experimental conditions.
Stability
Standard and the sample solutions were subjected to 24 h stability 
studies at room temperature and 2–8°C. The stability of these solutions 
was studied and observed for changes in the area and retention 
time of the peaks which were then compared with the pattern of the 
chromatogram of the freshly prepared solution.
Robustness
Robustness of the method was studied by slightly changes in 
experimental conditions such as flow rate and organic composition. 
Robustness on performed same instrument different chromatographic 
conditions.
Ruggedness
Ruggedness of the method was studied using different source of analyst, 
instruments, and columns with same experimental conditions.
RESULTS AND DISCUSSION
Method validation
In this method, system suitability, linearity, precision, accuracy, 
robustness, LOD, LOQ, forced degradation, and stability are validated 
for the selected NTP and PLS drugs.
System suitability
600 µg/ml of NTP and 1.0 µg/ml of PLS was prepared and injected into 
system. The retention times of NTP and PLS were found to be 3.025 and 
7.163 min, respectively. Resolution of the PLS was 11.28 from the NTP. 
The number of theoretical plate counts for NTP and PLS was 11,580 and 
6878, respectively. Tailing factor for NTP and PLS was 0.68 and 0.84, 
respectively. All the parameters found to be within the limit (Fig. 2).
Linearity
Linearity of the method was evaluated by preparing a standard solution 
containing 600 µg/ml of NTP and 1.0 µg/ml of PLS (100% targeted level 
of the assay concentration). Sequential dilutions were performed to give 
solutions at 10, 25, 50, 100, 125, and 150% of the target concentrations. 
These were injected and peak areas used to plot calibration curves against 
the concentration. The correlation coefficient values of these three 
analyte were 0.999. The results are shown in Table 1 and Figs 3 and 4.
LOD and LOQ
LOD and LOQ minimum concentration level at which the analyte can be 
reliably detected, quantified using the standard formulas (3.3 times σ/s 
and 10 times σ/s for LOD and LOQ, respectively). LOD values for NTP 
and PLS were 1.5005 and 0.0026 µg/ml and s/n values are 3 and 5, 
respectively. LOQ values for NTP and PLS were 3.001 and 0.0052 µg/ml 
and s/n values are 23 and 27, respectively.
Precision
Method precision was investigated by the analysis of six separately 
prepared samples of the same batch. From this, six separate sample 
solutions were injected and the peak areas obtained used to calculate 
mean and percentage of relative standard deviation (%RSD) values. The 
present method was found to be precise as %RSD of the <2%, and also, 
the percentage assay values were closed to be 100%. The results are 
given in Table 2 and Fig. 3.
Fig. 1: Photodiode array detector spectra for netupitant and palonosetron
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Accuracy
Accuracy was determined by recovery studies which were carried 
out in three different concentrations levels (50%, 100%, and 150%). 
APIs with concentration of 300, 600, and 900 µg/ml of NTP and 0.5, 
1.0, and 1.5 µg/ml of PLS were prepared. As per the test method, the 
test solution was injected three preparations each spike level and the 
assay was performed. The percentage of recovery values was found 
to be in the range of 100.08–100.24% of NTP and 100.38–100.65% 
of PLS. RSD values were found to be <2%. The results are given in 
Table 3.
Ruggedness
Ruggedness of the method was studied and showed that 
chromatographic patterns did not significantly change when different 
HPLC system, analyst, and column. The value of %RSD was <2% and 
exhibits the ruggedness of the developed method.
Robustness
Robustness of the method found to be %RSD should be <2%. Slightly 
variations were done in the optimized method parameters such as flow 
rate (±20%) and organic content in mobile phase (±5%). The results 
are given in Table 4.
Stability
Stability of standard and sample solutions is studied initial to 24 h in 
stored RT and 2–8°C. These solutions are analyzed initial to 24 h at 
different time intervals and results were recorded. The % deviation 
should not be more than 5.0%. There are no effects in storage conditions 
for NTP and PLS drugs. The results are shown in Table 5.
Forced degradation
Forced degradation conditions such as acidic, basic, oxidative, 
reduction, thermal, hydrolysis, and photolytic stresses were attempted 
as per the International Conference of Harmonization (ICH) guidelines 
Q2B. There is an effect of assay results. The results are shown in 
Table 6.
CONCLUSION
This method described the quantification of NTP and PLS in bulk and 
pharmaceutical formulation as per the ICH guidelines. The developed 
method was found to be accurate, precise, linear, and reliable. These 
two drugs are novel and strong discussion on developed method 
their validation. The advantage lies in the simplicity of sample 
preparation and economically fewer reagents were used. In addition, 
two compounds are eluted within 10 min. The proposed HPLC method 
was suitable resolution to precise quantification of the compounds. 
Statistical analysis of the experimental result indicates that the 
precision and reproducibility data are satisfactory. The developed 
chromatographic method can be effectively applied for routine analysis 
in drug research.
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NTP 60–900 µg/ml Y=8392x+27701 0.999
PLS 0.1–1.5 µg/ml Y=30888899x+158 0.999
NTP: Netupitant, PLS: Palonosetron
Table 2: Method precision results
Analyte Amount 
present 




NTP 600 µg/ml 100.26 1.05
PLS 1.0 µg/ml 100.05 0.56
NTP: Netupitant, %RSD: Percentage of relative standard deviation, 
PLS: Palonosetron
Table 3: Accuracy (recovery) study results










50 100.28 0.12 100.35 0.65
100 100.45 0.46 100.68 0.84
150 100.36 0.35 100.51 1.02
NTP: Netupitant, %RSD: Percentage of relative standard deviation, 
PLS: Palonosetron
Table 4: Robustness results
Drug 
name
Flow plus  
(1.2 ml/min) (%RSD)






NTP 0.28 0.14 0.35 1.02
PLS 0.36 0.57 0.87 0.63
NTP: Netupitant, %RSD: Percentage of relative standard deviation, PLS: Palonosetron
Fig. 2: Standard chromatogram
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